2A Pharma - Model 2AP02 - HER2 Positive Breast Cancer Vaccine Candidate

2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors was observed after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene AG, it was concluded that this vaccine strategy could help to establish active immunotherapy for breast-cancer patients. The Medical University of Vienna, Viral particles support prophylactic vaccination against breast cancer.